{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:26:26Z","timestamp":1785252386233,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Biol Endocrinol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The normal physiological function of LH requires a certain concentration range, but because of pituitary desensitization, even on the day of HCG, endogenous levels of LH are low in the follicular-phase long protocol. Therefore, our study aimed to determine whether it is necessary to monitor serum LH concentrations on the day of HCG (LH\n                      <jats:sub>HCG<\/jats:sub>\n                      ) and to determine whether there is an optimal LH\n                      <jats:sub>HCG<\/jats:sub>\n                      range to achieve the desired clinical outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study included 4502\u2009cycles of in vitro fertilization (IVF)\/intracytoplasmic sperm injection (ICSI) from January 1, 2016, to June 30, 2019, in a single department. The main outcome measures included retrieved eggs, available embryos, and live birth rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The LH\n                      <jats:sub>HCG<\/jats:sub>\n                      was divided into five groups: Group A (LH\u2009\u2264\u20090.5), Group B (0.5\u2009IU\/L\u2009&lt;\u2009LH\u2009\u2264\u20091.2\u2009IU\/L), Group C (1.2\u2009IU\/L\u2009&lt;\u2009LH\u2009\u2264\u20092.0\u2009IU\/L), Group D (2.0\u2009IU\/L\u2009&lt;\u2009LH\u2009\u2264\u20095.0\u2009IU\/L), Group E (LH\u2009&gt;\u20095\u2009IU\/L)\n                      <jats:bold>.<\/jats:bold>\n                      In terms of the numbers of retrieved eggs (15.22\u2009\u00b1\u20095.66 vs. 13.54\u2009\u00b1\u20095.23 vs. 12.90\u2009\u00b1\u20095.05 vs. 12.30\u2009\u00b1\u20094.88 vs. 9.6\u2009\u00b1\u20094.09), diploid fertilized oocytes (9.85\u2009\u00b1\u20094.70 vs. 8.69\u2009\u00b1\u20094.41 vs. 8.39\u2009\u00b1\u20094.33 vs. 7.78\u2009\u00b1\u20093.96 vs. 5.92\u2009\u00b1\u20092.78), embryos (7.90\u2009\u00b1\u20094.48 vs. 6.83\u2009\u00b1\u20094.03 vs. 6.44\u2009\u00b1\u20093.88 vs. 6.22\u2009\u00b1\u20093.62 vs. 4.40\u2009\u00b1\u20092.55), and high-quality embryos (4.32\u2009\u00b1\u20093.71 vs. 3.97\u2009\u00b1\u20093.42 vs. 3.76\u2009\u00b1\u20093.19 vs. 3.71\u2009\u00b1\u20093.04 vs. 2.52\u2009\u00b1\u20092.27), an increase in the LH\n                      <jats:sub>HCG<\/jats:sub>\n                      level showed a trend of a gradual decrease. However, there was no significant difference in clinical outcomes among the groups (66.67% vs. 64.33% vs. 63.21% vs. 64.48% vs. 63.33%). By adjusting for confounding factors, with an increase in LH\n                      <jats:sub>HCG<\/jats:sub>\n                      , the number of retrieved eggs decreased (OR: -0.351 95%CI \u2212\u20090.453-[\u2212\u20090.249]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In the follicular-phase long protocol among young women, monitoring LH\n                      <jats:sub>HCG<\/jats:sub>\n                      is recommended in the clinical guidelines to obtain the ideal number of eggs.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12958-022-00888-4","type":"journal-article","created":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T23:43:14Z","timestamp":1643758994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Is it necessary to monitor the serum luteinizing hormone (LH) concentration on the human chorionic gonadotropin (HCG) day among young women during the follicular-phase long protocol? A retrospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Wenjuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaozhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manman","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"888_CR1","first-page":"137","volume":"3","author":"D Shrestha","year":"2015","unstructured":"Shrestha D, La X, Feng HL. Comparison of different stimulation protocols used in in vitro fertilization: a review. Ann Transl Med. 2015;3:137.","journal-title":"Ann Transl Med"},{"key":"888_CR2","first-page":"29","volume":"9","author":"S Liu","year":"2018","unstructured":"Liu S, Deng C. Is LH supplementation necessary in the follicular-phase long protocol? J Reprod Med. 2018;9:29.","journal-title":"J Reprod Med"},{"key":"888_CR3","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1093\/humrep\/15.5.1003","volume":"15","author":"LG Westergaard","year":"2000","unstructured":"Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000;15:1003\u20138.","journal-title":"Hum Reprod"},{"key":"888_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1748-1716.1960.tb01823.x","volume":"47","author":"B Falck","year":"1959","unstructured":"Falck B. Site of production of oestrogen in rat ovary as studied in micro-transplants. Acta Physiol Scand Suppl. 1959;47:1\u2013101.","journal-title":"Acta Physiol Scand Suppl"},{"key":"888_CR5","volume-title":"Clinical gynecologic endocrinology and infertility","author":"MA Fritz","year":"2011","unstructured":"Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. Philadelphia: Wolters Kluwer Health\/Lippincott Williams & Wilkins; 2011."},{"key":"888_CR6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00001703-200206000-00004","volume":"14","author":"J Balasch","year":"2002","unstructured":"Balasch J, F\u00e1bregues F. Is luteinizing hormone needed for optimal ovulation induction? Curr Opin Obstet Gynecol. 2002;14:265\u201374.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"888_CR7","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1093\/oxfordjournals.humrep.a019357","volume":"11","author":"LG Westergaard","year":"1996","unstructured":"Westergaard LG, Erb K, Laursen S, Rasmussen PE, Rex S. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women. Hum Reprod. 1996;11:1209\u201313.","journal-title":"Hum Reprod"},{"key":"888_CR8","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1093\/humrep\/13.7.1788","volume":"13","author":"R Fleming","year":"1998","unstructured":"Fleming R, Lloyd F, Herbert M, Fenwick J, Griffiths T, Murdoch A. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod. 1998;13:1788\u201392.","journal-title":"Hum Reprod"},{"key":"888_CR9","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1093\/humrep\/15.7.1440","volume":"15","author":"R Fleming","year":"2000","unstructured":"Fleming R, Rehka P, Deshpande N, Jamieson ME, Yates RW, Lyall H. Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Hum Reprod. 2000;15:1440\u20135.","journal-title":"Hum Reprod"},{"issue":"1","key":"888_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.23736\/S0026-4806.19.06346-8","volume":"111","author":"M Terzic","year":"2020","unstructured":"Terzic M, Aimagambetova G, Garzon S. Ovulation induction in infertile women with endometriotic ovarian cysts: Current evidence and potential pitfalls [J]. Minerva Med. 2020;111(1):50\u201361.","journal-title":"Minerva Med."},{"issue":"5","key":"888_CR11","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00404-018-4906-2","volume":"298","author":"R Di Paola","year":"2018","unstructured":"Di Paola R, Garzon S, Giuliani S. Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman\u2019s age and markers of ovarian reserve [J]. Arch Gynecol Obstet. 2018;298(5):1029\u201335.","journal-title":"Arch Gynecol Obstet."},{"key":"888_CR12","doi-asserted-by":"crossref","unstructured":"Burnik Papler T, Vrtacnik Bokal E, Prosenc Zmrzljak U. PGR and PTX3 gene expression in cumulus cells from obese and normal weighting women after administration of long-acting recombinant follicle-stimulating hormone for controlled ovarian stimulation [J].\u00a0Arch Gynecol Obstetr. 2019;299(3):863\u201371.","DOI":"10.1007\/s00404-018-5031-y"},{"key":"888_CR13","first-page":"392","volume":"16","author":"N Nasiri","year":"2015","unstructured":"Nasiri N, Eftekhari-Yazdi P. An overview of the available methods for morphological scoring of pre-implantation embryos in in vitro fertilization. Cell J. 2015;16:392\u2013405.","journal-title":"Cell J"},{"key":"888_CR14","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.fertnstert.2017.06.005","volume":"108","author":"Z Fernando","year":"2017","unstructured":"Fernando Z. G. David a, Slike D. the international glossary on infertility and fertility care. Fertil Steril. 2017;108:393\u2013406.","journal-title":"Fertil Steril"},{"key":"888_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0015-0282(16)55188-7","volume":"58","author":"D Navot","year":"1992","unstructured":"Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249\u201361.","journal-title":"Fertil Steril"},{"key":"888_CR16","volume-title":"Preterm labour and birth","author":"National Collaborating Centre for Women\u2019s and Children\u2019s Health (UK)","year":"2015","unstructured":"National Collaborating Centre for Women\u2019s and Children\u2019s Health (UK). Preterm labour and birth. UK: National Institute for Health and Care Excellence; 2015."},{"key":"888_CR17","volume-title":"Clinical practice and improvement of assisted reproductive technology","author":"X Liang","year":"2018","unstructured":"Liang X. Clinical practice and improvement of assisted reproductive technology. China: People\u2019s Health Publishing House; 2018."},{"key":"888_CR18","first-page":"704","volume":"48","author":"XX Wu","year":"2019","unstructured":"Wu XX, Chen DL, Zheng YP. The effect of LH concentration on hCG day on the outcome of in vitro fertilization in the follicular-phase long protocol. J Huazhong Univ Sci Technol (Health Sci). 2019;48:704\u20137.","journal-title":"J Huazhong Univ Sci Technol (Health Sci)"},{"key":"888_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0015-0282(16)57443-3","volume":"63","author":"U Sungurtekin","year":"1995","unstructured":"Sungurtekin U, Jansen RP. Profound luteinizing hormone suppression after stopping the gonadotropin-releasing hormone-agonist leuprolide acetate. Fertil Steril. 1995;63:663\u20135.","journal-title":"Fertil Steril"},{"key":"888_CR20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3109\/09513599209015549","volume":"6","author":"FJ Broekmans","year":"1992","unstructured":"Broekmans FJ, Bernardus RE, Berkhout G, Schoemaker J. Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation: decapeptyl CR. Gynecol Endocrinol. 1992;6:153\u201361.","journal-title":"Gynecol Endocrinol"},{"key":"888_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1472-6483(10)61186-8","volume":"12","author":"C Alviggi","year":"2006","unstructured":"Alviggi C, Clarizia R, Mollo A, Ranieri A, De Placido G. Outlook: who needs LH in ovarian stimulation? Reprod BioMed Online. 2006;12:599\u2013607.","journal-title":"Reprod BioMed Online"},{"key":"888_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.rbmo.2011.03.023","volume":"23","author":"PC Wong","year":"2011","unstructured":"Wong PC, Qiao J, Ho C, Ramaraju GA, Wiweko B, Takehara Y, et al. Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective. Reprod BioMed Online. 2011;23:81\u201390.","journal-title":"Reprod BioMed Online"},{"key":"888_CR23","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1093\/humrep\/del221","volume":"21","author":"K Lossl","year":"2006","unstructured":"Lossl K, Andersen AN, Loft A, Freiesleben NL, Bangsb\u00f8ll S, Andersen CY. Androgen priming using aromatase inhibitor and hCG during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols. Hum Reprod. 2006;21:2593\u2013600.","journal-title":"Hum Reprod"},{"key":"888_CR24","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1093\/humrep\/dei101","volume":"20","author":"S Bjercke","year":"2005","unstructured":"Bjercke S, Fedorcsak P, Abyholm T, Storeng R, Ertzeid G, Oldereid N, et al. IVF\/ICSI outcome and serum LH concentration on day 1 of ovarian stimulation with recombinant FSH under pituitary suppression. Hum Reprod. 2005;20:2441\u20137.","journal-title":"Hum Reprod"},{"key":"888_CR25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.fertnstert.2018.01.003","volume":"109","author":"C Alviggi","year":"2018","unstructured":"Alviggi C, Conforti A, Esteves SC, Andersen CY, Bosch E, B\u00fchler K, et al. Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review. Fertil Steril. 2018;109:644\u201364.","journal-title":"Fertil Steril"}],"container-title":["Reproductive Biology and Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-022-00888-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12958-022-00888-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12958-022-00888-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T23:43:58Z","timestamp":1643759038000},"score":1,"resource":{"primary":{"URL":"https:\/\/rbej.biomedcentral.com\/articles\/10.1186\/s12958-022-00888-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["888"],"URL":"https:\/\/doi.org\/10.1186\/s12958-022-00888-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-885747\/v1","asserted-by":"object"}]},"ISSN":["1477-7827"],"issn-type":[{"value":"1477-7827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of the Third Affiliated Hospital of Zhengzhou University (2021\u2013105).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}